Pre-made Astegolimab benchmark antibody ( Whole mAb, anti-IL1RL1/ST2 therapeutic antibody, Anti-DER4/FIT-1/IL33R/T1 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Astegolimab biosimilar, Whole mAb, Anti-IL1RL1/ST2 Antibody: Anti-DER4/FIT-1/IL33R/T1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

The IL-33/ST2 pathway is linked with asthma susceptibility. Inhaled allergens, pollutants, and respiratory viruses, which trigger asthma exacerbations, induce release of IL-33, an epithelial-derived "alarmin." Astegolimab, a human IgG2 mAb, selectively inhibits the IL-33 receptor, ST2.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-033-1mg	1mg	3090
GMP-Bios-ab-033-10mg	10mg	Inquiry
GMP-Bios-ab-033-100mg	100mg	Inquiry
GMP-Bios-ab-033-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Astegolimab biosimilar, Whole mAb, Anti-IL1RL1/ST2 Antibody: Anti-DER4/FIT-1/IL33R/T1 therapeutic antibody
INN Name	Astegolimab
Target	IL1RL1
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG2
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2019
Year Recommended	2020
Companies	Amgen;Genentech;University of Leicester
Conditions Approved	na
Conditions Active	Allergic asthma;Atopic dermatitis;Chronic obstructive pulmonary disease
Conditions Discontinued	Asthma;Rhinosinusitis
Development Tech	na